(Q37847337)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

review article

1 reference

title

Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Gareth J Morgan

series ordinal

1

1 reference

24 August 2017

language of work or name

1 reference

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

77 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

S24-30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

1 reference

7 January 2021

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Multiple myeloma: evolving genetic events and host interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Synergistic antimyeloma effects of zoledronate and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Multiple myeloma. Clinical practice guidelines in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

Bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2811%2970005-1

7 January 2021

10.1016/S1040-8428(11)70005-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353177%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference